An increasing array of substances that inhibit HIF1α, encompassing chemical inhibitors (topotecan, PX-478, YC-1, 2-ME2, BAY87-2243, and digoxin) as well as antisense oligonucleotides (EZN-2968), have demonstrated promising anti-tumor effects by impeding tumor growth and metastasis across various preclinical models [145,146]. This evidence concerns the gene HIF1A and neoplasm.